- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07680790
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
June 26, 2026 updated by: Bristol-Myers Squibb
A Phase III, Randomized, Open-label Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy as First-Line Therapy in Patients With EGFR-Mutant Locally Advanced or Metastatic Non-small Cell Lung Cancer
The purpose of this study is to evaluate izalontamab brengitecan (iza-bren) combined with osimertinib in participants with previously untreated, locally advanced or metastatic EGFR-mutant NSCLC, compared to osimertinib alone or osimertinib combined with platinum-based chemotherapy
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
850
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: First line of the email MUST contain NCT # and Site #.
Study Contact Backup
- Name: BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
- Phone Number: 855-907-3286
- Email: Clinical.Trials@bms.com
Study Locations
-
-
New South Wales
-
Camperdown, New South Wales, Australia, 2050
- Local Institution - 0424
-
Contact:
- Site 0424
-
Westmead, New South Wales, Australia, 2145
- Local Institution - 0439
-
Contact:
- Site 0439
-
-
Queensland
-
Greenslopes, Queensland, Australia, 4120
- Local Institution - 0511
-
Contact:
- Site 0511
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Local Institution - 0492
-
Contact:
- Site 0492
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Local Institution - 0447
-
Contact:
- Site 0447
-
-
Western Australia
-
Murdoch, Western Australia, Australia, 6150
- Local Institution - 0437
-
Contact:
- Site 0437
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G1Z2
- Local Institution - 0059
-
Contact:
- Site 0059
-
-
British Columbia
-
Abbotsford British Columbia, British Columbia, Canada, V2S0C2
- Local Institution - 0494
-
Vancouver, British Columbia, Canada, V5Z4E6
- Local Institution - 0056
-
Contact:
- Site 0056
-
-
Ontario
-
Oakville, Ontario, Canada, L6M 0L8
- Local Institution - 0533
-
Contact:
- Site 0533
-
Oshawa, Ontario, Canada, L1G2B9
- Local Institution - 0043
-
Contact:
- Site 0043
-
Toronto, Ontario, Canada, M4N3M5
- Local Institution - 0012
-
Contact:
- Site 0012
-
Toronto, Ontario, Canada, M5G2M9
- Local Institution - 0045
-
-
Quebec
-
Laval, Quebec, Canada, H7M3L9
- Local Institution - 0407
-
Montreal, Quebec, Canada, H3T1E2
- Local Institution - 0058
-
Contact:
- Site 0058
-
Montreal, Quebec, Canada, H4A3J1
- Local Institution - 0057
-
Contact:
- Site 0057
-
-
Saskatchewan
-
Regina, Saskatchewan, Canada, S4T1A5
- Local Institution - 0040
-
Contact:
- Site 0040
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100142
- Local Institution - 0517
-
Contact:
- Site 0517
-
Beijing, Beijing Municipality, China, 101149
- Local Institution - 0458
-
Contact:
- Site 0458
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, China, 400030
- Local Institution - 0470
-
Contact:
- Site 0470
-
-
Fujian
-
Fuzhou, Fujian, China, 350001
- Local Institution - 0493
-
Contact:
- Site 0493
-
Fuzhou, Fujian, China, 350014
- Local Institution - 0457
-
Contact:
- Site 0457
-
-
Guangdong
-
Dongguan Shi, Guangdong, China, 523059
- Local Institution - 0326
-
Contact:
- Site 0326
-
Guangzhou, Guangdong, China, 510080
- Local Institution - 0331
-
Contact:
- Site 0331
-
Zhongshan, Guangdong, China, 528403
- Local Institution - 0478
-
Contact:
- Site 0478
-
-
Guangxi
-
Guilin, Guangxi, China, 541199
- Local Institution - 0321
-
Contact:
- Site 0321
-
Nanning, Guangxi, China, 530021
- Local Institution - 0328
-
Contact:
- Site 0328
-
-
Hainan
-
Haikou, Hainan, China, 570000
- Local Institution - 0330
-
Contact:
- Site 0330
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150081
- Local Institution - 0343
-
Contact:
- Site 0343
-
-
Henan
-
Weihui Shi, Henan, China, 453100
- Local Institution - 0341
-
Contact:
- Site 0341
-
Zhengzhou, Henan, China, 450000
- Local Institution - 0480
-
Contact:
- Site 0480
-
Zhengzhou, Henan, China, 450008
- Local Institution - 0423
-
Contact:
- Site 0423
-
-
Hubei
-
Jingzhou, Hubei, China
- Local Institution - 0483
-
Contact:
- Site 0483
-
Wuhan, Hubei, China, 430022
- Local Institution - 0450
-
Contact:
- Site 0450
-
-
Hunan
-
Changsha, Hunan, China, 410007
- Local Institution - 0482
-
Contact:
- Site 0482
-
Changsha Shi, Hunan, China, 410008
- Local Institution - 0467
-
Contact:
- Site 0467
-
Changsha Shi, Hunan, China, 410013
- Local Institution - 0306
-
Contact:
- Site 0306
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210029
- Local Institution - 0347
-
Contact:
- Site 0347
-
-
Liaoning
-
Shenyang, Liaoning, China, 110042
- Local Institution - 0332
-
Contact:
- Site 0332
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710038
- Local Institution - 0464
-
Contact:
- Site 0464
-
-
Shandong
-
Binzhou, Shandong, China, 256603
- Local Institution - 0479
-
Contact:
- Site 0479
-
Weifang Shi, Shandong, China, 261000
- Local Institution - 0469
-
Contact:
- Site 0469
-
-
Shanghai Municipality
-
Shanghai Shi, Shanghai Municipality, China, 200120
- Local Institution - 0319
-
Contact:
- Site 0319
-
-
Shanxi
-
Taiyuan, Shanxi, China, 30001
- Local Institution - 0316
-
Contact:
- Site 0316
-
Taiyuan, Shanxi, China, 30013
- Local Institution - 0463
-
Contact:
- Site 0463
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Local Institution - 0456
-
Contact:
- Site 0456
-
Chengdu, Sichuan, China, 610041
- Local Institution - 0471
-
Contact:
- Site 0471
-
Dazhou Shi, Sichuan, China, 635000
- Local Institution - 0320
-
Contact:
- Site 0320
-
Yibin, Sichuan, China, 644000
- Local Institution - 0472
-
Contact:
- Site 0472
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, China, 300060
- Local Institution - 0452
-
Contact:
- Site 0452
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310022
- Local Institution - 0312
-
Contact:
- Site 0312
-
-
-
-
-
Brest, France, 29200
- Local Institution - 0073
-
Contact:
- Site 0073
-
Caen, France, 14076
- Local Institution - 0066
-
Contact:
- Site 0066
-
Toulouse, France, 31059
- Local Institution - 0070
-
Contact:
- Site 0070
-
-
Bouches-Du-Rhône
-
Marseille, Bouches-Du-Rhône, France, 13915
- Local Institution - 0074
-
Contact:
- Site 0074
-
-
Côte-D'Or
-
Dijon, Côte-D'Or, France, 21079
- Local Institution - 0063
-
Contact:
- Site 0063
-
-
Loire Atlantique
-
Nantes, Loire Atlantique, France, 44093
- Local Institution - 0075
-
Contact:
- Site 0075
-
-
Nan
-
La Tronche, Nan, France, 38700
- Local Institution - 0064
-
Contact:
- Site 0064
-
Lyon, Nan, France, 69373
- Local Institution - 0116
-
Contact:
- Site 0116
-
Paris, Nan, France, 75014
- Local Institution - 0109
-
Contact:
- Site 0109
-
-
Rhône
-
Bron, Rhône, France, 69677
- Local Institution - 0062
-
Contact:
- Site 0062
-
-
Val-De-Marne
-
Villejuif, Val-De-Marne, France, 94805
- Local Institution - 0069
-
Contact:
- Site 0069
-
-
Île-de-France Region
-
Paris, Île-de-France Region, France, 75248
- Local Institution - 0071
-
Contact:
- Site 0071
-
-
-
-
-
Giessen, Germany, 35392
- Local Institution - 0445
-
Contact:
- Site 0445
-
-
Baden-Wurttemberg
-
Gerlingen, Baden-Wurttemberg, Germany, 70839
- Local Institution - 0112
-
Contact:
- Site 0112
-
Ulm, Baden-Wurttemberg, Germany, 89081
- Local Institution - 0111
-
Wangen, Baden-Wurttemberg, Germany, 88239
- Local Institution - 0110
-
-
Bavaria
-
Munich, Bavaria, Germany, 81377
- Local Institution - 0001
-
Contact:
- Site 0001
-
Regensburg, Bavaria, Germany, 93053
- Local Institution - 0105
-
Contact:
- Site 0105
-
-
Hesse
-
Frankfurt am Main, Hesse, Germany, 60389
- Local Institution - 0446
-
Contact:
- Site 0446
-
-
Lower Saxony
-
Oldenburg, Lower Saxony, Germany, 26121
- Local Institution - 0106
-
Contact:
- Site 0106
-
-
North Rhine-Westphalia
-
Cologne, North Rhine-Westphalia, Germany, 50937
- Local Institution - 0100
-
Contact:
- Site 0100
-
Dortmund, North Rhine-Westphalia, Germany, 44263
- Local Institution - 0243
-
Contact:
- Site 0243
-
Essen, North Rhine-Westphalia, Germany, 45147
- Local Institution - 0104
-
Contact:
- Site 0104
-
Hemer, North Rhine-Westphalia, Germany, 58675
- Local Institution - 0117
-
Contact:
- Site 0117
-
Münster, North Rhine-Westphalia, Germany, 48149
- Local Institution - 0101
-
Contact:
- Site 0101
-
-
Saxony
-
Dresden, Saxony, Germany, 1307
- Local Institution - 0103
-
Contact:
- Site 0103
-
Leipzig, Saxony, Germany, 4103
- Local Institution - 0412
-
Contact:
- Site 0412
-
-
Schleswig-Holstein
-
Großhansdorf, Schleswig-Holstein, Germany, 22927
- Local Institution - 0108
-
Contact:
- Site 0108
-
Lübeck, Schleswig-Holstein, Germany, 23538
- Local Institution - 0239
-
Contact:
- Site 0239
-
-
-
-
Gujarat
-
Vadodara, Gujarat, India, 361790
- Local Institution - 0225
-
Contact:
- Site 0225
-
-
Haryana
-
Badsa, Haryana, India, 124105
- Local Institution - 0444
-
Contact:
- Site 0444
-
Gurgaon, Haryana, India, 122001
- Local Institution - 0337
-
Contact:
- Site 0337
-
-
Karnataka
-
Belagavi, Karnataka, India, 590010
- Local Institution - 0436
-
Contact:
- Site 0436
-
-
Maharashtra
-
Pune, Maharashtra, India, 411013
- Local Institution - 0215
-
Contact:
- Site 0215
-
-
Punjab
-
Mohali, Punjab, India, 140901
- Local Institution - 0233
-
Contact:
- Site 0233
-
-
Tamil Nadu
-
Chennai, Tamil Nadu, India, 600035
- Local Institution - 0222
-
Contact:
- Site 0222
-
-
-
-
-
Bergamo, Italy, 24128
- Local Institution - 0093
-
Contact:
- Site 0093
-
Brescia, Italy, 25123
- Local Institution - 0289
-
Contact:
- Site 0289
-
Milan, Italy, 20133
- Local Institution - 0089
-
Contact:
- Site 0089
-
Milan, Italy, 20141
- Local Institution - 0087
-
Contact:
- Site 0087
-
Milan, Italy, 20142
- Local Institution - 0238
-
Contact:
- Site 0238
-
Pavia, Italy, 27100
- Local Institution - 0091
-
Contact:
- Site 0091
-
Verona, Italy, 37126
- Local Institution - 0088
-
Contact:
- Site 0088
-
-
Forli-Cesena
-
Meldola, Forli-Cesena, Italy, 47014
- Local Institution - 0236
-
Contact:
- Site 0236
-
-
Turin
-
Candiolo, Turin, Italy, 10060
- Local Institution - 0094
-
Contact:
- Site 0094
-
-
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japan, 464-8681
- Local Institution - 0262
-
Contact:
- Site 0262
-
-
Ehime
-
Toon-Shi, Ehime, Japan, 791-0295
- Local Institution - 0128
-
Contact:
- Site 0128
-
-
Fukuoka
-
Kurume-Shi, Fukuoka, Japan, 830-0011
- Local Institution - 0136
-
Contact:
- Site 0136
-
-
Kanagawa
-
Yokohama, Kanagawa, Japan, 241-8515
- Local Institution - 0121
-
Contact:
- Site 0121
-
-
Miyagi
-
Sendai, Miyagi, Japan, 980-0873
- Local Institution - 0122
-
Contact:
- Site 0122
-
-
Okayama-ken
-
Okayama, Okayama-ken, Japan, 700-8558
- Local Institution - 0433
-
Contact:
- Site 0433
-
-
Osaka
-
Hirakata-Shi, Osaka, Japan, 573-1191
- Local Institution - 0125
-
Contact:
- Site 0125
-
Osakasayama-Shi, Osaka, Japan, 589-8511
- Local Institution - 0129
-
Contact:
- Site 0129
-
-
Shizuoka
-
Hamamatsu, Shizuoka, Japan, 431-3192
- Local Institution - 0141
-
Contact:
- Site 0141
-
-
Tokyo-To
-
Chūōku, Tokyo-To, Japan, 104-0045
- Local Institution - 0137
-
Contact:
- Site 0137
-
Kōtoku, Tokyo-To, Japan, 135-8550
- Local Institution - 0414
-
Contact:
- Site 0414
-
-
-
-
-
Gyeongsangnam-do, South Korea, 050612
- Local Institution - 0139
-
Contact:
- Site 0139
-
Seoul, South Korea, 120-752
- Local Institution - 0135
-
Contact:
- Site 0135
-
Seoul, South Korea, 3080
- Local Institution - 0131
-
Contact:
- Site 0131
-
Seoul, South Korea, 8308
- Local Institution - 0126
-
Contact:
- Site 0126
-
-
Daegu
-
Buk-Gu, Daegu, South Korea, 41404
- Local Institution - 0138
-
Contact:
- Site 0138
-
Dalseo, Daegu, South Korea, 42601
- Local Institution - 0506
-
Contact:
- Site 0506
-
-
Gyeonggi-do
-
Goyang-si, Gyeonggi-do, South Korea, 410-769
- Local Institution - 0127
-
Contact:
- Site 0127
-
Seongnam-si, Gyeonggi-do, South Korea, 13620
- Local Institution - 0133
-
Contact:
- Site 0133
-
-
Jeollanam-do
-
Hwasun-Gun, Jeollanam-do, South Korea, 58128
- Local Institution - 0134
-
Contact:
- Site 0134
-
-
North Chungcheong
-
Cheongju-si, North Chungcheong, South Korea, 361-711
- Local Institution - 0140
-
Contact:
- Site 0140
-
-
Seoul
-
Seocho -Gu, Seoul, South Korea, 6591
- Local Institution - 0124
-
Contact:
- Site 0124
-
Songpa-Gu, Seoul, South Korea, 138-736
- Local Institution - 0123
-
Contact:
- Site 0123
-
-
-
-
-
A Coruña, Spain, 15006
- Local Institution - 0242
-
Contact:
- Site 0242
-
Jaén, Spain, 23007
- Local Institution - 0144
-
Contact:
- Site 0144
-
Jaén, Spain, 23007
- Local Institution - 0226
-
Contact:
- Site 0226
-
Jerez de la Frontera, Spain, 11407
- Local Institution - 0149
-
Contact:
- Site 0149
-
Madrid, Spain, 28041
- Local Institution - 0148
-
Contact:
- Site 0148
-
Málaga, Spain, 29010
- Local Institution - 0150
-
Contact:
- Site 0150
-
Valencia, Spain, 46009
- Local Institution - 0241
-
Contact:
- Site 0241
-
-
Madrid
-
Majadahonda, Madrid, Spain, 28222
- Local Institution - 0143
-
Contact:
- Site 0143
-
-
Seville
-
Seville, Seville, Spain, 41013
- Local Institution - 0147
-
Contact:
- Site 0147
-
-
-
-
-
Taichung, Taiwan, 40201
- Local Institution - 0418
-
Contact:
- Site 0418
-
Tainan, Taiwan, 70428
- Local Institution - 0420
-
Contact:
- Site 0420
-
Taipei, Taiwan, 100225
- Local Institution - 0419
-
Contact:
- Site 0419
-
-
Kaohsiung
-
Kaohsiung City, Kaohsiung, Taiwan, 82445
- Local Institution - 0229
-
Contact:
- Site 0229
-
-
New Taipei
-
New Taipei City, New Taipei, Taiwan, 23561
- Local Institution - 0230
-
Contact:
- Site 0230
-
-
Taichung
-
Taipei, Taichung, Taiwan, 112
- Local Institution - 0216
-
Contact:
- Site 0216
-
-
Taiwan
-
Gaoxiongka, Taiwan, Taiwan, 807
- Local Institution - 0227
-
Contact:
- Site 0227
-
-
Taoyuan
-
Taoyuan City, Taoyuan, Taiwan, 33378
- Local Institution - 0221
-
Contact:
- Site 0221
-
-
-
-
-
Adana, Turkey (Türkiye), 1060
- Local Institution - 0014
-
Contact:
- Site 0014
-
Adana, Turkey (Türkiye), 1370
- Local Institution - 0019
-
Contact:
- Site 0019
-
Ankara, Turkey (Türkiye), 6680
- Local Institution - 0008
-
Contact:
- Site 0008
-
Ankara, Turkey (Türkiye), 6800
- Local Institution - 0003
-
Contact:
- Site 0003
-
Antalya, Turkey (Türkiye), 07100
- Local Institution - 0015
-
Contact:
- Site 0015
-
Istanbul, Turkey (Türkiye), 34214
- Local Institution - 0041
-
Contact:
- Site 0041
-
Istanbul, Turkey (Türkiye), 34295
- Local Institution - 0039
-
Contact:
- Site 0039
-
Izmir, Turkey (Türkiye), 35110
- Local Institution - 0050
-
Contact:
- Site 0050
-
Izmir, Turkey (Türkiye), 35530
- Local Institution - 0037
-
Contact:
- Site 0037
-
-
Diyarbakır
-
Sur, Diyarbakır, Turkey (Türkiye), 21200
- Local Institution - 0021
-
Contact:
- Site 0021
-
-
Istanbul
-
Pendik, Istanbul, Turkey (Türkiye), 34340
- Local Institution - 0265
-
Contact:
- Site 0265
-
-
-
-
California
-
Beverly Hills, California, United States, 90211
- Local Institution - 0212
-
Contact:
- Site 0212
-
Fullerton, California, United States, 92835
- Local Institution - 0504
-
Contact:
- Site 0504
-
La Jolla, California, United States, 92093
- Local Institution - 0357
-
Contact:
- Site 0357
-
-
Colorado
-
Pueblo, Colorado, United States, 81003
- Local Institution - 0520
-
Contact:
- Site 0520
-
-
Florida
-
Orlando, Florida, United States, 32806
- Local Institution - 0366
-
Contact:
- Site 0366
-
Palm Bay, Florida, United States, 32901
- Local Institution - 0519
-
Contact:
- Site 0519
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96813
- Local Institution - 0210
-
Contact:
- Site 0210
-
-
Illinois
-
Ottawa, Illinois, United States, 61350
- Local Institution - 0207
-
Contact:
- Site 0207
-
-
Maryland
-
Baltimore, Maryland, United States, 21202
- Local Institution - 0503
-
Contact:
- Site 0503
-
Silver Spring, Maryland, United States, 20904
- Local Institution - 0523
-
Contact:
- Site 0523
-
-
Minnesota
-
Edina, Minnesota, United States, 55435
- Local Institution - 0521
-
Contact:
- Site 0521
-
Saint Paul, Minnesota, United States, 55102
- Local Institution - 0364
-
Contact:
- Site 0364
-
-
Missouri
-
St Louis, Missouri, United States, 63110
- Local Institution - 0403
-
Contact:
- Site 0403
-
-
Nebraska
-
Omaha, Nebraska, United States, 68198
- Local Institution - 0402
-
Contact:
- Site 0402
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03756
- Local Institution - 0290
-
Contact:
- Site 0290
-
-
New Jersey
-
New Brunswick, New Jersey, United States, 08901
- Local Institution - 0183
-
Contact:
- Site 0183
-
-
New York
-
New York, New York, United States, 10021
- Local Institution - 0153
-
Contact:
- Site 0153
-
The Bronx, New York, United States, 10461
- Local Institution - 0157
-
Contact:
- Site 0157
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28204
- Local Institution - 0385
-
Contact:
- Site 0385
-
-
Ohio
-
Sandusky, Ohio, United States, 44870
- Local Institution - 0438
-
Contact:
- Site 0438
-
-
Oregon
-
Portland, Oregon, United States, 97213
- Local Institution - 0404
-
Contact:
- Site 0404
-
-
Pennsylvania
-
Easton, Pennsylvania, United States, 18045
- Local Institution - 0487
-
Contact:
- Site 0487
-
-
South Dakota
-
Sioux Falls, South Dakota, United States, 57105
- Local Institution - 0200
-
Contact:
- Site 0200
-
-
Tennessee
-
Memphis, Tennessee, United States, 38120
- Local Institution - 0199
-
Contact:
- Site 0199
-
-
Texas
-
Beaumont, Texas, United States, 77702
- Local Institution - 0522
-
Contact:
- Site 0522
-
Dallas, Texas, United States, 75246
- Local Institution - 0525
-
Contact:
- Site 0525
-
San Antonio, Texas, United States, 78217
- Local Institution - 0529
-
Contact:
- Site 0529
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Local Institution - 0411
-
Contact:
- Site 0411
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Local Institution - 0165
-
Contact:
- Site 0165
-
Fairfax, Virginia, United States, 22031
- Local Institution - 0530
-
Contact:
- Site 0530
-
Winchester, Virginia, United States, 22601
- Local Institution - 0528
-
Contact:
- Site 0528
-
-
Washington
-
Seattle, Washington, United States, 98104
- Local Institution - 0283
-
Contact:
- Site 0283
-
-
West Virginia
-
Morgantown, West Virginia, United States, 26505
- Local Institution - 0502
-
Contact:
- Site 0502
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Participants must have histologically or cytologically confirmed non-squamous NSCLC, newly diagnosed locally advanced (Stage IIIB/IIIC), metastatic (Stage IVA/IVB), or recurrent disease not amenable to curative surgery or definitive radiotherapy and requiring systemic treatment
- Participants must have documented EGFR-TKI-sensitizing mutation (exon 19 deletion or exon 21 L858R substitution)
- Participants must have measurable extracranial disease per RECIST v1.1 as assessed by the investigator
- Participants must have ECOG Performance Status 0-1
Exclusion Criteria:
- Participants must not have unstable, symptomatic, or uncontrolled CNS metastases, including brain, leptomeningeal disease, and/or spinal cord compression
- Participants must not have history of ILD/pneumonitis requiring treatment with steroids (≥ Grade 2), or current or suspected ILD/pneumonitis
- Participants must not have clinically significant cardiac disease
- Other protocol-defined inclusion/exclusion criteria apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Arm A
|
Specified dose on specified days
Other Names:
Specified dose on days
|
|
Active Comparator: Arm B
|
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Progression-Free Survival (PFS) using blinded independent central review (BICR) assessment as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
Time Frame: Up to approximately 3 years
|
Up to approximately 3 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Overall Survival (OS)
Time Frame: Up to approximately 5 years
|
Up to approximately 5 years
|
|
PFS assessed by the investigator as per RECIST v1.1
Time Frame: Up to approximately 3 years
|
Up to approximately 3 years
|
|
Second Progression-Free Survival (PFS2) as assessed by the Investigator
Time Frame: Up to approximately 5 years
|
Up to approximately 5 years
|
|
Objective Response Rate (ORR) assessed by the BICR as per RECIST v1.1
Time Frame: Up to approximately 3 years
|
Up to approximately 3 years
|
|
Objective Response Rate (ORR) assessed by the investigator as per RECIST v1.1
Time Frame: Up to approximately 3 years
|
Up to approximately 3 years
|
|
Disease Control Rate (DCR) assessed by the BICR as per RECIST v1.1
Time Frame: Up to approximately 3 years
|
Up to approximately 3 years
|
|
Disease Control Rate (DCR) assessed by the investigator as per RECIST v1.1
Time Frame: Up to approximately 3 years
|
Up to approximately 3 years
|
|
Duration of Response (DOR) assessed by the BICR as per RECIST v1.1
Time Frame: Up to approximately 3 years
|
Up to approximately 3 years
|
|
Duration of Response (DOR) assessed by the investigator as per RECIST v1.1
Time Frame: Up to approximately 3 years
|
Up to approximately 3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
September 30, 2026
Primary Completion (Estimated)
December 30, 2031
Study Completion (Estimated)
December 30, 2031
Study Registration Dates
First Submitted
June 26, 2026
First Submitted That Met QC Criteria
June 26, 2026
First Posted (Actual)
July 2, 2026
Study Record Updates
Last Update Posted (Actual)
July 2, 2026
Last Update Submitted That Met QC Criteria
June 26, 2026
Last Verified
June 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Respiratory Tract Diseases
- Lung Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Lung Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Amino Acids, Peptides, and Proteins
- Organic Chemicals
- Heterocyclic Compounds
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Inorganic Chemicals
- Chlorine Compounds
- Nitrogen Compounds
- Coordination Complexes
- Guanine
- Hypoxanthines
- Purinones
- Purines
- Glutamates
- Amino Acids, Acidic
- Amino Acids
- Amino Acids, Dicarboxylic
- Platinum Compounds
- Pemetrexed
- Carboplatin
- Cisplatin
- osimertinib
Other Study ID Numbers
- CA244-0020
- 2026-526486-21 (Other Identifier: EU CTR)
- U1111-1338-8955 (Other Identifier: WHO)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria.
Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
IPD Sharing Time Frame
See Plan Description
IPD Sharing Access Criteria
See Plan Description
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Small Cell Lung Cancer
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
University of California, DavisNational Cancer Institute (NCI)RecruitingNon Small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IV | Non-small Cell Lung Cancer Stage IIIC | Non-small Cell Lung Cancer UnresectableUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
Royal Marsden NHS Foundation TrustUniversity of Cambridge; Royal Brompton & Harefield NHS Foundation Trust; Institute... and other collaboratorsRecruitingNon Small Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer | Locally Advanced NSCLC - Non-Small Cell Lung Cancer | Oncogene-addicted Non Small Cell Lung Cancer | Early-stage Operable Non Small Cell Lung Cancer | Stage 2/3 Operable Non Small Cell Lung CancerUnited Kingdom
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bristol-Myers SquibbTerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma | Non-Squamous Non-Small...United States
-
Brigham and Women's HospitalFood and Drug Administration (FDA)Active, not recruitingAdvanced Non-squamous Non-small-cell Lung Cancer | Advanced Squamous Non Small Cell Lung CancerUnited States
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
Megan Daly, MDBristol-Myers Squibb; National Cancer Institute (NCI); TransgeneCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung CancerUnited States
Clinical Trials on Carboplatin
-
Eisai Inc.CompletedCancerUnited States, Austria, India
-
Anhui Provincial Cancer HospitalNot yet recruiting
-
Samyang Biopharmaceuticals CorporationCompleted
-
Shanghai Pulmonary Hospital, Shanghai, ChinaNot yet recruiting
-
Zhejiang Cancer HospitalRecruiting
-
NHS Greater Glasgow and ClydeCompletedOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity CancerUnited Kingdom, Australia, New Zealand
-
Duke UniversityCompletedBrain and Central Nervous System TumorsUnited States, Canada
-
Sun Yat-sen UniversityNot yet recruiting
-
National Cancer Institute (NCI)CompletedBreast Cancer | Ovarian CancerUnited States
-
Tang-Du HospitalRecruitingHead & Neck CancerChina